Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an update.
Telix Pharmaceuticals Limited announced the cessation of certain securities, including share rights and share appreciation rights, due to unmet conditions. This development may impact the company’s capital structure and could have implications for its stakeholders, as it reflects adjustments in the company’s financial and operational strategies.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company aims to address significant unmet medical needs in oncology and other diseases.
Average Trading Volume: 2,935,168
Technical Sentiment Signal: Sell
Current Market Cap: A$5.13B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.